Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer: primary analysis of the phase II INSPIRE trial

Autor: van Wilpe, S., Kloots, I.S.H., Slootbeek, P.H.J., den Brok, M., Westdorp, H., Franken, M.D., Coskunturk, M., Osinga, T., Bloemendal, H., Adema, G., Smeenk, R.J., Nagarajah, J., van Ipenburg, J., Kroeze, L.I., Ligtenberg, M.J.L., Schalken, J., Gerritsen, W.R., Mehra, N.

Publikováno v: In Annals of Oncology

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Real-world data on the management of pazopanib-induced liver toxicity in routine care of renal cell cancer and soft tissue sarcoma patients.

Autor: Westerdijk, K., Krens, S. D., Steeghs, N., van der Graaf, W. T. A., Tjwa, E. T. T. L., Westdorp, H., Desar, I. M. E., van Erp, N. P.

Publikováno v: Cancer Chemotherapy & Pharmacology; Apr2024, Vol. 93 Issue 4, p353-364, 12p

Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer.

Autor: Tolmeijer SH; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., van Wilpe S; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Geerlings MJ; Department of Human Genetics, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., von Rhein D; Department of Human Genetics, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Smilde TJ; Department of Medical Oncology, Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, The Netherlands., Kloots ISH; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Westdorp H; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Coskuntürk M; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Oving IM; Department of Medical Oncology, Ziekenhuisgroep Twente, Almelo, The Netherlands., van Ipenburg JA; Department of Pathology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., van der Heijden AG; Department of Urology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Hofste T; Department of Human Genetics, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Weiss MM; Department of Human Genetics, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Schalken JA; Department of Urology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Gerritsen WR; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Ligtenberg MJL; Department of Human Genetics, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands; Department of Pathology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands., Mehra N; Department of Medical Oncology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, The Netherlands. Electronic address: Niven.mehra@radboudumc.nl.

Publikováno v: European urology oncology [Eur Urol Oncol] 2024 Apr; Vol. 7 (2), pp. 282-291. Date of Electronic Publication: 2023 Sep 04.

LBA72 Nivolumab 3mg/kg and ipilimumab 1mg/kg (nivo3/ipi1) in molecularly selected patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)

Autor: Mehra, N., Van Wilpe, S., Westdorp, H., Kloots, I., Slootbeek, P., Brok, M. den, Franken, M., Coskuntürk, M., Bloemendal, H., Nagarajah, J., van Ipenburg, J., Kroeze, L., Ligtenberg, M., Schalken, J.A., Gerritsen, W.R.

Publikováno v: In Annals of Oncology September 2024 35 Supplement 2:S1259-S1260